Abstract
B-cell neoplasms have the sixth highest mortality incidence and one of the largest rates of increase of all malignancies. Frequent relapse and the development of refractory disease in this patient group have stimulated research to find alternative treatments. The use of unconjugated antibodies offers a new approach to the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This article will explore the pharmacology, dosage, and administration guidelines as well as side effect management of the available drugs in this classification. Expectations for future approaches to the treatment of B-cell neoplasms will be discussed.